Drug Trial Radar · NCT05117554
Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Nov 9, 2021
Primary completion
Feb 17, 2023
Study completion Feb 17, 2023
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and tolerability, pharmacokinetic, and pharmacodynamic profile, and drug-drug interaction (DDI) of casdatifan in healthy participants.
Conditions
- Healthy Participants
Interventions
casdatifanDrug
Capsule
PlaceboDrug
Capsule
MidazolamDrug
Syrup solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 21.5 Weeks
- Number of Participants With Abnormal Changes From Baseline in Laboratory Parameter ValuesTime frame: Baseline; Up to 21.5 Weeks
- Number of Participants With Abnormal Changes from Baseline in Vital Sign ValuesTime frame: Baseline; Up to 21.5 Weeks
- Maximum Observed Plasma Concentration (Cmax) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
- Area Under the Plasma Concentration Time Curve From Hour 0 to the Last Sample With Measurable Plasma Concentrations (AUClast) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
- Time of Occurrence of Cmax (tmax) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
- Apparent Terminal Elimination Rate Constant (λz) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
- Terminal Half-Life (t1/2) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
- Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUCinf) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
- Apparent Volume of Distribution of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
- Apparent Total Body Clearance of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational Site
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.